Gain Therapeutics, Inc.
Gain Therapeutics, Inc. scores highest on Anchor (51) and lowest on Price (14). Its PosiPenta is 31.51 out of 100, weaker than most similar companies.
On the Penta Grid this week, Gain Therapeutics, Inc. is Grid #731 of 837 in the Healthcare sector in United States, and Grid #3,525 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Gain Therapeutics, Inc. | 31.51 | 14 | 38 | 20 | 35 | 51 |
| Heron Therapeutics, Inc. | 25.16 | 7 | 60 | 28 | 1 | 30 |
| Boundless Bio, Inc. | 51.27 | 42 | 45 | 78 | 35 | 57 |
| MindWalk Holdings Corp. | 38.80 | 6 | 69 | 42 | 27 | 51 |
| RenovoRx, Inc. | 41.36 | 12 | 65 | 45 | 42 | 43 |
| Gossamer Bio, Inc. | 32.36 | 0 | 34 | 4 | 97 | 27 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -2.52 |
| P/B ratio | 4.87 |
EEarnings
| Trailing EPS | ₹-47.36 |
| Forward EPS | ₹-65.12 |
NNitro
| Price | 119.34 |
| 52-week high | 411.06 |
| 52-week low | 116.97 |
| Fall from 52-week high | 71.0% |
TTorque
| Return on equity (ROE) | -268.30% |
| Debt-to-equity | 0.05 |
AAnchor
| Beta (price swings) | 0.19 |
| Market cap | ₹520 Cr |
| Insider holding | 2.23% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Gain Therapeutics, Inc.'s PosiPenta score?
Gain Therapeutics, Inc.'s PosiPenta is 31.51 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Gain Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Gain Therapeutics, Inc. is Grid #731 of 837 in the Healthcare sector in United States, and Grid #3,525 of 4,000 in United States.
Which PosiPenta pillar is strongest for Gain Therapeutics, Inc.?
Anchor (stability and dividends), with a score of 51 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Gain Therapeutics, Inc.?
Price (valuation), with a score of 14 out of 100: much weaker than most similar companies.
Has Gain Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.32 points, from 28.19 to 31.51.
PositoAI is for research and education only and is not investment advice.